Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes
In a US cohort of 52,971 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide initiation was associated with a lower one-year risk of major adverse cardiovascular events…